Trials / Completed
CompletedNCT03809962
Efficacy and Safety of Ostenil® Plus in the Treatment of Coxarthrosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 170 (actual)
- Sponsor
- TRB Chemedica AG · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
PMCF study to observe the Routine application of Ostenil® Plus in the Treatment of pain and restricted mobility in degenerative and traumatic changes of the Hip Joint.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Ostenil® Plus | Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation |
Timeline
- Start date
- 2019-02-15
- Primary completion
- 2025-05-14
- Completion
- 2025-05-14
- First posted
- 2019-01-18
- Last updated
- 2025-06-05
Locations
7 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03809962. Inclusion in this directory is not an endorsement.